Vertex has backed out of its in vivo gene editing collaboration with Verve Therapeutics before reaching the clinic. Verve, which attributed Vertex’s action to its changing R&D priorities, is ...

KING OF PRUSSIA, Pa., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ: VERX) (“Vertex” or the “Company”), a leading global provider of indirect tax solutions, today announced ...

In the latest quarter, 8 analysts provided ratings for Vertex VERX, showcasing a mix of bullish and bearish perspectives. The table below provides a concise overview of recent ratings by analysts ...

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...

In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands against other stocks that Jim Cramer discusses. In a recent appearance on CNBC’s ...

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

One label you’re likely to see is the OEKO-TEX Standard 100. This is awarded to brands whose textiles have been lab tested and cleared of harmful substances. We’re taking a closer look at this ...

Vertex Pharma has made its name with treatment for cystic fibrosis, but has big plans in cell and genetic therapies – and has just chalked up fast-track status from the FDA for a cell-based ...

See reviews below to learn more or submit your own review. How do I know I can trust these reviews about The Standard Insurance Company? How do I know I can trust these reviews about The Standard ...

2-Year U.S. Treasury Note Continuous Contract $103.535 0.047 0.05% 5-Year U.S. Treasury Note Continuous Contract $108.070 0.148 0.14% 10-Year U.S. Treasury Note Continuous Contract $111.297 0.297 ...

2-Year U.S. Treasury Note Continuous Contract $103.395-0.109-0.11% 5-Year U.S. Treasury Note Continuous Contract $107.539-0.281-0.26% 10-Year U.S. Treasury Note Continuous Contract $110.469-0.406 ...

The end of the Vertex-Verve collaboration comes as investors are reevaluating once sky-high expectations for the gene editing industry as commercial realities set in. Shares of Verve and top companies ...